Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Cytokine profiling in active and quiescent SLE reveals distinct patient subpopulations
Authors: John A. Reynolds
Eoghan M. McCarthy
Sahena Haque
Pintip Ngamjanyaporn
Jamie C. Sergeant
Elaine Lee
Eileen Lee
Stephen A. Kilfeather
Ben Parker
Ian N. Bruce
Christie Hospital NHS Foundation Trust
Faculty of Medicine, Ramathibodi Hospital, Mahidol University
University of Manchester
Aeirtec Ltd
Keywords: Immunology and Microbiology;Medicine
Issue Date: 9-Aug-2018
Citation: Arthritis Research and Therapy. Vol.20, No.1 (2018)
Abstract: © 2018 The Author(s). Background: Patients with SLE display marked clinical and immunlogical heterogeneity. The purpose of the study was to investigate patterns of serum cytokines in patients with active and stable systemic lupus erythematosus (SLE) and to determine how they relate to clinical phenotype. Methods: Serum levels of 10 cytokines were measured retrospectively in a cohort of patients with SLE and in healthy controls using a high-sensitivity multiplex bead array. Disease activity was determined using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and British Isles Lupus Assessment Group (BILAG-2004) indices. Logistic regression models were used to determine the association between cytokine levels and active SLE. Principal component analysis (PCA) and cluster analysis was then used to identify subgroups of patients on the basis of cytokine levels. Results: Serum chemokine (C-X-C motif) ligand 10 (CXCL10) and CXCL13 were significantly higher in patients with SLE compared to healthy controls. Two cytokines (pentraxin-related protein (PTX3) and CXCL10) were significantly higher in patients with active disease after adjustment for potential confounding factors. Measurement of four cytokines (CXCL10, IL-10, IL-21 and PTX3) significantly improved the performance of a model to identify patients with clinically active disease. Cluster analysis revealed that the patients formed 3 distinct groups, characterised by higher levels of interferon alpha (IFNα) and B lymphocyte stimulator (BLyS) (group 1), increased CXCL10 and CXCL13 (group 2) or low levels of cytokines (group 3). Group 2 had significantly lower serum complement and higher anti-double-stranded DNA antibodies and increased prevalence of inflammatory arthritis. Conclusions: Multiplex analysis has identified a serum cytokine signature for active SLE. Within the SLE population distinct cytokine subgroups were identified, with differing clinical and immunological phenotypes that appeared stable over time. Assessment of cytokine profiles may reveal unique insights into disease heterogeneity.
ISSN: 14786362
Appears in Collections:Scopus 2018

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.